# Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

> **NCT06391008** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 44 (estimated)

## Conditions studied

- Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** Stereotactic radiotherapy
- **DRUG:** Evoximab
- **DRUG:** Pemetrexed
- **DRUG:** Albumin Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06391008
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-30
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391008, "Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06391008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*